untitled design

The new listed pharmaceutical companies monopolize the increases in the Stock Market motivated by the vaccines against Covid-19

The behavior of the stock prices during 2020 of the pharmaceutical companies that develop vaccines against Covid-19 has been uneven since all the positive returns were concentrated in the companies that have recently traded in Bag, while the consolidated laboratories saw their share price fall.

Specifically, of the main companies developing vaccines against Covid-19, returns have been concentrated in BioNTech, Modern, Novavax, and Cuevas. Although their years of foundation vary and all have more than a decade of life, all, except Novavax, went public in the last two years.

On the contrary, the main laboratories involved in the creation of vaccines, with registrations on the Stock Market that far exceed 20 or 30 years, such as Pfizer, Sanofi, GSK O Astrazeneca observed negative returns during 2020.

Pfizer posted almost flat growth over the past year. At the end of March 2020, when the pandemic generated panic in the world financial markets, the drop in the price compared to December 31, 2019 reached 27.3%, to stand at $ 26.99. In fact, even the rally in early December, when the price reached $ 42.56, did not exceed the stock data observed in 2018.

On the contrary, your partner BioNTech registered a positive evolution, with an improvement in the Stock Market of up to 150% at the end of 2020. In fact, if one looks at the peak of December 10, when the price reached its historical maximum of $ 129.54, the This figure is even higher, with an improvement compared to December 31, 2019 of 282%. The German company debuted on the markets in October 2019 and, since then, its shares have increased in price in the markets six times.

In the same way, the evolution in the US Nasdaq electronic market of Modern it has also been very positive, with an improvement of 470% for the year as a whole. At its maximum peak on December 8, the return reached 768.4%, standing at 169.86 dollars per share. The company debuted in the markets in 2018 and until 2020 it had not registered any trend of stable stock increase.

Classic pharmaceuticals are falling apart

The British Laboratory AstraZeneca, which collaborates with Oxford University in the development of its vaccine against the disease, it registered a drop of 2.71% during the whole of 2020. Despite the negative data, the company’s price has recovered compared to March, when it accumulated a decrease from the beginning of the year of 18.22%. However, despite the negative data that closed the year, the price of the British firm has been in the range of all-time highs this year.

European Pharmaceuticals Sanofi and GSK had an even more negative evolution than AstraZeneca. The French company closed in 2020 with a drop of around 12% for the year as a whole, while the British company fell by almost 24%.

Of the large laboratories involved in the development of vaccines, only Johnson & Johnson it closed the year with a stock increase of more than 6%. In fact, since the stock market crisis in March, its share price has improved by 40% and, in general, throughout 2020 the price was in a range of all-time highs compared to other years.

Novavax It was one of the pharmaceutical companies with the best return observed in 2020, with an increase of more than 2,870%. At the maximum peak recorded in August, the increase reached 4,385%, placing the price at 178.51 dollars. However, that price still stayed away from the nearly $ 300 it posted in 2001.

On your side, Curevac it was the one that performed the best in the markets. After debuting on the stock market in August, it quickly registered rises in its price, until it closed the year with a return of 4,200%. At its highs on December 9, the rise was more than 6.920%.

You may also like

Dior, anatomy of freedom
Entertainment
Susan

Dior, anatomy of freedom

This article is published in issue 18 of Vanity Fair on newsstands until April 30, 2024. Join your hands proudly.

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular